Moreover, inhibiting USP25 could temper KRAS signaling in pancreatic, lung, and colon cancer cells carrying various activating mutations in KRAS and for one of the mutants, KRASQ61H, no direct inhibitors are available (Fig. 4B). Here, KRAS is linked to malignant colon neoplasm.